Notice: Internet Explorer 11 users may encounter issues loading pages throughout the website. Please turn on IE-11’s compatibility mode while we work to resolve the issue.

>

MEETINGS / EVENTS

RSS

May 05 - 07 2014, 12:00 AM - 12:00 AM

2014 ASA Legislative Conference

>

FDA MEDWATCH ALERTS

April 21, 2014

Lidocaine HCI Injection, USP, by Hospira: Recall - Visible Particulates

Summary:

Lidocaine HCI Injection USP by Hospira Recall Visible Particulates

April 18, 2014

Propofol Injectable Emulsion, USP by Hospira: Recall - Visible Particulates

Summary:

Propofol Injectable Emulsion USP by Hospira Recall Visible Particulates

April 18, 2014

FDA MedWatch - ARKON Anesthesia Delivery System with Version 2.0 Software by Spacelabs Healthcare: Class I Recall

Summary:

FDA MedWatch Class I Recall 4 18 14

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-14CE

... Read more »

Single Copies, Member Price: $360

ASA Responds to Federal Trade Commission's Proposed Statement on ACO Antitrust Enforcement

Tuesday, May 31, 2011

In conjunction with the release of the Centers for Medicare and Medicaid Services (CMS) proposed rule on Accountable Care Organizations (ACOs), the Federal Trade Commission (FTC) released a proposed statement of antitrust enforcement policy regarding ACOs participating in the Medicare Shared Savings Program. The ASA recently submitted a letter to the FTC in response to the proposed statement.  Next week, the ASA will submit comprehensive comments to CMS on the proposed ACO rule.

In the letter to the FTC, the ASA states it is in general agreement with comments made by the American Medical Association. The ASA letter goes on to detail how the proposed statement would impact anesthesiologists specifically.   

ASA concludes the letter by stating: “To ensure the success of the Shared Savings Program, it is critical for CMS and the FTC/DOJ to develop a Shared Savings Program and associated antitrust clearance process that enables the majority of physicians to develop, lead and actively participate in ACOs.  While ASA supports the application of the rule of reason to ACOs, we have serious reservations about the market power implications and their impact on anesthesiologists.“

Click here to read the letter submitted by ASA.

Click here to read the FTC proposed statement.

Click here for the latest information on the work ASA is doing regarding ACOs.

 

 

« Back to Washington Alerts